Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

Trial Profile

Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Blinatumomab (Primary) ; Crisantaspase; Daunorubicin; Dexamethasone; Ifosfamide; Methotrexate; Pegaspargase; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 27 Mar 2017 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
    • 27 Mar 2017 Planned primary completion date changed from 1 Jan 2019 to 30 Jan 2020.
    • 02 Mar 2016 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top